A role for oxytocin in the etiology and treatment of schizophrenia

Frontiers in Endocrinology

Volumn 6, Issue JUN, 2015, Pages

  Rich, Megan Elizabeth ^a   Caldwell, Heather Kingsley ^a  

^a KENT STATE UNIVERSITY   (United States)

Author keywords

Dopamine; Early life stress; Glutamate; Sensorimotor gating; Social cognition

Indexed keywords

OXYTOCIN;

AUTISM; CEREBROSPINAL FLUID; EARLY LIFE STRESS; HALLUCINATION; HIPPOCAMPUS; HUMAN; NEUROTRANSMITTER RELEASE; NONHUMAN; PERINATAL STRESS; POLYDIPSIA; REVIEW; SCHIZOPHRENIA; SENSORIMOTOR CORTEX; SOCIAL BEHAVIOR; SOCIAL COGNITION; SOCIAL INTERACTION; SPATIAL MEMORY;

EID: 84936763970     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2015.00090     Document Type: Review

References (212)

1. Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry (1993) 50:85-94. doi: 10.1001/archpsyc.1993.01820140007001
2. American Psychiatric Association. Diagnositc and Statistical Manual of Mental Disorders. Arlington, VA: American Psychiatric Association (2013).
3. Gogtay N, Rapoport J. Clozapine use in children and adolescents. Expert Opin Pharmacother (2008) 9:459-65. doi:10.1517/14656566.9.3.459
4. N.I.O.M. Health. Schizophrenia. Washington, DC: U.S. Department of Health and Human Services (2009).
5. Fenton WS, McGlashan TH. Natural history of schizophrenia subtypes. II. Positive and negative symptoms and long-term course. Arch Gen Psychiatry (1991) 48:978-86. doi:10.1001/archpsyc.1991.01810350018003
6. Mueser KT, McGurk SR. Schizophrenia. Lancet (2004) 363:2063-72. doi:10.1016/S0140-6736(04)16458-1
7. Andreasen NC. Symptoms, signs, and diagnosis of schizophrenia. Lancet (1995) 346:477-81. doi:10.1016/S0140-6736(95)91325-4
8. da Silva Alves F, Figee M, van Amelsvoort T, Veltman D, de Haan L. The revised dopamine hypothesis of schizophrenia: evidence from pharmacological MRI studies with atypical antipsychotic medication. Psychopharmacol Bull (2008) 41:121-32. doi:10.1016/S0920-9964(08)70291-3
9. Walter H, Kammerer H, Frasch K, Spitzer M, Abler B. Altered reward functions in patients on atypical antipsychotic medication in line with the revised dopamine hypothesis of schizophrenia. Psychopharmacology (2009) 206:121-32. doi:10.1007/s00213-009-1586-4
10. Pogarell O, Koch W, Karch S, Dehning S, Muller N, Tatsch K, et al. Dopaminergic neurotransmission in patients with schizophrenia in relation to positive and negative symptoms. Pharmacopsychiatry (2012) 45(Suppl 1):S36-41. doi:10.1055/s-0032-1306313
11. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (1996) 124:57-73. doi:10.1007/BF02245606
12. Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull (2003) 29:15-31. doi:10.1093/oxfordjournals.schbul.a006986
13. Naber D, Lambert M. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs (2009) 23:649-59. doi:10.2165/00023210-200923080-00002
14. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on quality of life of second- vs. first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry (2006) 63:1079-87. doi:10.1001/archpsyc.63.10.1079
15. Lewis S, Lieberman J. CATIE and CUtLASS: can we handle the truth? Br J Psychiatry (2008) 192:161-3. doi:10.1192/bjp.bp.107.037218
16. Davidson M, Reichenberg A, Rabinowitz J, Weiser M, Kaplan Z, Mark M. Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. Am J Psychiatry (1999) 156:1328-35.
17. Cornblatt BA, Erlenmeyer-Kimling L. Global attentional deviance as a marker of risk for schizophrenia: specificity and predictive validity. J Abnorm Psychol (1985) 94:470-86. doi:10.1037/0021-843X.94.4.470
18. LaCrosse AL, Olive MF. Neuropeptide systems and schizophrenia. CNS Neurol Disord Drug Targets (2013) 12:619-32. doi:10.2174/1871527311312050010
19. Coyle JT. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol (2006) 26:365-84. doi:10.1007/s10571-006-9062-8
20. Foster DJ, Choi DL, Conn PJ, Rook JM. Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophrenia. Neuropsychiatr Dis Treat (2014) 10:183-91. doi:10.2147/NDT.S55104
21. Deidda G, Bozarth IF, Cancedda L. Modulation of GABAergic transmission in development and neurodevelopmental disorders: investigating physiology and pathology to gain therapeutic perspectives. Front Cell Neurosci (2014) 8:119. doi:10.3389/fncel.2014.00119
22. Meneses A. Memory formation and memory alterations: 5-HT6 and 5-HT7 receptors, novel alternative. Rev Neurosci (2014) 25:325-56. doi:10.1515/revneuro-2014-0001
23. Di Pilato P, Niso M, Adriani W, Romano E, Travaglini D, Berardi F, et al. Selective agonists for serotonin 7 (5-HT7) receptor and their applications in preclinical models: an overview. Rev Neurosci (2014) 25:401-15. doi:10.1515/revneuro-2014-0009
24. Nikiforuk A. The procognitive effects of 5-HT6 receptor ligands in animal models of schizophrenia. Rev Neurosci (2014) 25:367-82. doi:10.1515/revneuro-2014-0005
25. Tan H, Ahmad T, Loureiro M, Zunder J, Laviolette SR. The role of cannabinoid transmission in emotional memory formation: implications for addiction and schizophrenia. Front Psychiatry (2014) 5:73. doi:10.3389/fpsyt.2014.00073
26. Kim SK, Park HJ, Seok H, Jeon HS, Chung JH, Kang WS, et al. Association study between monoamine oxidase A (MAOA) gene polymorphisms and schizophrenia: lack of association with schizophrenia and possible association with affective disturbances of schizophrenia. Mol Biol Rep (2014) 41:3457-64. doi:10.1007/s11033-014-3207-5
27. Souza RP, Ismail P, Meltzer HY, Kennedy JL. Variants in the oxytocin gene and risk for schizophrenia. Schizophr Res (2010) 121:279-80. doi:10.1016/j.schres.2010.04.019
28. Souza RP, de Luca V, Meltzer HY, Lieberman JA, Kennedy JL. Schizophrenia severity and clozapine treatment outcome association with oxytocinergic genes. Int J Neuropsychopharmacol (2010) 13:793-8. doi:10.1017/S1461145710000167
29. Bujanow W. Letter: is oxytocin an anti-schizophrenic hormone? Can Psychiatr Assoc J (1974) 19:323.
30. Feifel D, Macdonald K, Nguyen A, Cobb P, Warlan H, Galangue B, et al. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol Psychiatry (2010) 68:678-80. doi:10.1016/j.biopsych.2010.04.039
31. Nishimori K, Takayanagi Y, Yoshida M, Kasahara Y, Young LJ, Kawamata M. New aspects of oxytocin receptor function revealed by knockout mice: sociosexual behaviour and control of energy balance. Prog Brain Res (2008) 170:79-90. doi:10.1016/S0079-6123(08)00408-1
32. Takayanagi Y, Yoshida M, Bielsky IF, Ross HE, Kawamata M, Onaka T, et al. Pervasive social deficits, but normal parturition, in oxytocin receptor-deficient mice. Proc Natl Acad Sci USA (2005) 102:16096-101. doi:10.1073/pnas.0505312102
33. Winslow JT, Insel TR. The social deficits of the oxytocin knockout mouse. Neuropeptides (2002) 36:221-9. doi:10.1054/npep.2002.0909
34. Carson DS, Cornish JL, Guastella AJ, Hunt GE, McGregor IS. Oxytocin decreases methamphetamine self-administration, methamphetamine hyperactivity, and relapse to methamphetamine-seeking behaviour in rats. Neuropharmacology (2010) 58:38-43. doi:10.1016/j.neuropharm.2009.06.018
35. Sarnyai Z, Szabo G, Kovacs GL, Telegdy G. Oxytocin attenuates the cocaine-induced exploratory hyperactivity in mice. Neuroreport (1990) 1:200-2. doi:10.1097/00001756-199011000-00006
36. Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev (2001) 81:629-83.
37. Lee HJ, Macbeth AH, Pagani JH, Young WS III. Oxytocin: the great facilitator of life. Prog Neurobiol (2009) 88:127-51. doi:10.1016/j.pneurobio.2009.04.001
38. Tomizawa K, Iga N, Lu YF, Moriwaki A, Matsushita M, Li ST, et al. Oxytocin improves long-lasting spatial memory during motherhood through MAP kinase cascade. Nat Neurosci (2003) 6:384-90. doi:10.1038/nn1023
39. Bohus B, Urban I, van Wimersma Greidanus TB, de Wied D. Opposite effects of oxytocin and vasopressin on avoidance behaviour and hippocampal theta rhythm in the rat. Neuropharmacology (1978) 17:239-47. doi:10.1016/0028-3908(78)90107-7
40. De Wied D. Long term effect of vasopressin on the maintenance of a conditioned avoidance response in rats. Nature (1971) 232:58-60. doi:10.1038/232058a0
41. Kovacs GL, Vecsei L, Telegdy G. Opposite action of oxytocin to vasopressin in passive avoidance behavior in rats. Physiol Behav (1978) 20:801-2. doi:10.1016/0031-9384(78)90309-8
42. Caldwell HK. Neurobiology of sociability. Adv Exp Med Biol (2012) 739:187-205. doi:10.1007/978-1-4614-1704-0_12
43. Carter CS. Neuroendocrine perspectives on social attachment and love. Psychoneuroendocrinology (1998) 23:779-818. doi:10.1016/S0306-4530(98)00055-9
44. vnas-Moberg KU. Physiological and endocrine effects of social contact. Ann N Y Acad Sci (1997) 807:146-63. doi:10.1111/j.1749-6632.1997.tb51917.x
45. Zak PJ, Stanton AA, Ahmadi S. Oxytocin increases generosity in humans. PLoS One (2007) 2:e1128. doi:10.1371/journal.pone.0001128
46. Feldman R, Weller A, Zagoory-Sharon O, Levine A. Evidence for a neuroendocrinological foundation of human affiliation: plasma oxytocin levels across pregnancy and the postpartum period predict mother-infant bonding. Psychol Sci (2007) 18:965-70. doi:10.1111/j.1467-9280.2007.02010.x
47. Barraza JA, Zak PJ. Empathy toward strangers triggers oxytocin release and subsequent generosity. Ann N Y Acad Sci (2009) 1167:182-9. doi:10.1111/j.1749-6632.2009.04504.x
48. Goldman M, Marlow-O'Connor M, Torres I, Carter CS. Diminished plasma oxytocin in schizophrenic patients with neuroendocrine dysfunction and emotional deficits. Schizophr Res (2008) 98:247-55. doi:10.1016/j.schres.2007.09.019
49. Rosenfeld AJ, Lieberman JA, Jarskog LF. Oxytocin, dopamine, and the amygdala: a neurofunctional model of social cognitive deficits in schizophrenia. Schizophr Bull (2011) 37:1077-87. doi:10.1093/schbul/sbq015
50. Beckmann H, Lang RE, Gattaz WF. Vasopressin-oxytocin in cerebrospinal fluid of schizophrenic patients and normal controls. Psychoneuroendocrinology (1985) 10:187-91. doi:10.1016/0306-4530(85)90056-3
51. Linkowski P, Geenen V, Kerkhofs M, Mendlewicz J, Legros JJ. Cerebrospinal fluid neurophysins in affective illness and in schizophrenia. Eur Arch Psychiatry Neurol Sci (1984) 234:162-5. doi:10.1007/BF00461555
52. Glovinsky D, Kalogeras KT, Kirch DG, Suddath R, Wyatt RJ. Cerebrospinal fluid oxytocin concentration in schizophrenic patients does not differ from control subjects and is not changed by neuroleptic medication. Schizophr Res (1994) 11:273-6. doi:10.1016/0920-9964(94)90021-3
53. Rubin LH, Carter CS, Drogos L, Pournajafi-Nazarloo H, Sweeney JA, Maki PM. Peripheral oxytocin is associated with reduced symptom severity in schizophrenia. Schizophr Res (2010) 124:13-21. doi:10.1016/j.schres.2010.09.014
54. Rubin LH, Carter CS, Drogos L, Jamadar R, Pournajafi-Nazarloo H, Sweeney JA, et al. Sex-specific associations between peripheral oxytocin and emotion perception in schizophrenia. Schizophr Res (2011) 130:266-70. doi:10.1016/j.schres.2011.06.002
55. Teltsh O, Kanyas-Sarner K, Rigbi A, Greenbaum L, Lerer B, Kohn Y. Oxytocin and vasopressin genes are significantly associated with schizophrenia in a large Arab-Israeli pedigree. Int J Neuropsychopharmacol (2012) 15:309-19. doi:10.1017/S1461145711001374
56. Watanabe Y, Kaneko N, Nunokawa A, Shibuya M, Egawa J, Someya T. Oxytocin receptor (OXTR) gene and risk of schizophrenia: case-control and family-based analyses and meta-analysis in a Japanese population. Psychiatry Clin Neurosci (2012) 66:622. doi:10.1111/j.1440-1819.2012.02396.x
57. Montag C, Brockmann EM, Bayerl M, Rujescu D, Muller DJ, Gallinat J. Oxytocin and oxytocin receptor gene polymorphisms and risk for schizophrenia: a case-control study. World J Biol Psychiatry (2013) 14:500-8. doi:10.3109/15622975.2012.677547
58. Mai JK, Berger K, Sofroniew MV. Morphometric evaluation of neurophysin-immunoreactivity in the human brain: pronounced inter-individual variability and evidence for altered staining patterns in schizophrenia. J Hirnforsch (1993) 34:133-54.
59. Goldman MB, Gomes AM, Carter CS, Lee R. Divergent effects of two different doses of intranasal oxytocin on facial affect discrimination in schizophrenic patients with and without polydipsia. Psychopharmacology (2011) 216:101-10. doi:10.1007/s00213-011-2193-8
60. Macdonald K, Feifel D. Oxytocin in schizophrenia: a review of evidence for its therapeutic effects. Acta Neuropsychiatr (2012) 24:130-46. doi:10.1111/j.1601-5215.2011.00634.x
61. Bakermans-Kranenburg MJ, van IJMH. Sniffing around oxytocin: review and meta-analyses of trials in healthy and clinical groups with implications for pharmacotherapy. Transl Psychiatry (2013) 3:e258. doi:10.1038/tp.2013.34
62. McEwen BB. Brain-fluid barriers: relevance for theoretical controversies regarding vasopressin and oxytocin memory research. Adv Pharmacol (2004) 50:531-92. doi:10.1016/S1054-3589(04)50016-9
63. Churchland PS, Winkielman P. Modulating social behavior with oxytocin: how does it work? What does it mean? Horm Behav (2012) 61:392-9. doi:10.1016/j.yhbeh.2011.12.003
64. Dal Monte O, Noble PL, Turchi J, Cummins A, Averbeck BB. CSF and blood oxytocin concentration changes following intranasal delivery in Macaque. PLoS One (2014) 9:e103677. doi:10.1371/journal.pone.0103677
65. Striepens N, Kendrick KM, Hanking V, Landgraf R, Wullner U, Maier W, et al. Elevated cerebrospinal fluid and blood concentrations of oxytocin following its intranasal administration in humans. Sci Rep (2013) 3:3440. doi:10.1038/srep03440
66. Neumann ID, Maloumby R, Beiderbeck DI, Lukas M, Landgraf R. Increased brain and plasma oxytocin after nasal and peripheral administration in rats and mice. Psychoneuroendocrinology (2013) 38:1985-93. doi:10.1016/j.psyneuen.2013.03.003
67. De Dreu CK, Baas M, Roskes M, Sligte DJ, Ebstein RP, Chew SH, et al. Oxytonergic circuitry sustains and enables creative cognition in humans. Soc Cogn Affect Neurosci (2014) 9(8):1159-65. doi:10.1093/scan/nst094
68. Davis MC, Lee J, Horan WP, Clarke AD, McGee MR, Green MF, et al. Effects of single dose intranasal oxytocin on social cognition in schizophrenia. Schizophr Res (2013) 147:393-7. doi:10.1016/j.schres.2013.04.023
69. Pedersen CA, Gibson CM, Rau SW, Salimi K, Smedley KL, Casey RL, et al. Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia. Schizophr Res (2011) 132:50-3. doi:10.1016/j.schres.2011.07.027
70. Averbeck BB, Bobin T, Evans S, Shergill SS. Emotion recognition and oxytocin in patients with schizophrenia. Psychol Med (2012) 42:259-66. doi:10.1017/S0033291711001413
71. Feifel D, Macdonald K, Cobb P, Minassian A. Adjunctive intranasal oxytocin improves verbal memory in people with schizophrenia. Schizophr Res (2012) 139:207-10. doi:10.1016/j.schres.2012.05.018
72. Modabbernia A, Rezaei F, Salehi B, Jafarinia M, Ashrafi M, Tabrizi M, et al. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia: an 8-week, randomized, double-blind, placebo-controlled study. CNS Drugs (2013) 27:57-65. doi:10.1007/s40263-012-0022-1
73. Green MF, Horan WP. Social cognition in schizophrenia. Curr Dir Psychol Sci (2010) 19:243-8. doi:10.1177/0963721410377600
74. Velasques B, Machado S, Paes F, Cunha M, Sanfim A, Budde H, et al. Sensorimotor integration and psychopathology: motor control abnormalities related to psychiatric disorders. World J Biol Psychiatry (2011) 12:560-73. doi:10.3109/15622975.2010.551405
75. Lepage M, Bodnar M, Bowie CR. Neurocognition: clinical and functional outcomes in schizophrenia. Can J Psychiatry (2014) 59:5-12.
76. Levy DL, Sereno AB, Gooding DC, O'Driscoll GA. Eye tracking dysfunction in schizophrenia: characterization and pathophysiology. Curr Top Behav Neurosci (2010) 4:311-47. doi:10.1007/7854_2010_60
77. Allen AJ, Griss ME, Folley BS, Hawkins KA, Pearlson GD. Endophenotypes in schizophrenia: a selective review. Schizophr Res (2009) 109:24-37. doi:10.1016/j.schres.2009.01.016
78. Isohanni M, Isohanni I, Koponen H, Koskinen J, Laine P, Lauronen E, et al. Developmental precursors of psychosis. Curr Psychiatry Rep (2004) 6:168-75. doi:10.1007/s11920-004-0061-5
79. Haijma SV, Van Haren N, Cahn W, Koolschijn PC, Hulshoff Pol HE, Kahn RS. Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects. Schizophr Bull (2013) 39:1129-38. doi:10.1093/schbul/sbs118
80. Fazel S, Gulati G, Linsell L, Geddes JR, Grann M. Schizophrenia and violence: systematic review and meta-analysis. PLoS Med (2009) 6:e1000120. doi:10.1371/journal.pmed.1000120
81. Witt K, van Dorn R, Fazel S. Risk factors for violence in psychosis: systematic review and meta-regression analysis of 110 studies. PLoS One (2013) 8:e55942. doi:10.1371/journal.pone.0055942
82. Braga RJ, Reynolds GP, Siris SG. Anxiety comorbidity in schizophrenia. Psychiatry Res (2013) 210:1-7. doi:10.1016/j.psychres.2013.07.030
83. Veenema AH, Bredewold R, Neumann ID. Opposite effects of maternal-separation on intermale and maternal aggression in C57BL/6 mice: link to hypothalamic vasopressin and oxytocin immunoreactivity. Psychoneuroendocrinology (2007) 32:437-50. doi:10.1016/j.psyneuen.2007.02.008
84. Tsuda MC, Yamaguchi N, Ogawa S. Early life stress disrupts peripubertal development of aggression in male mice. Neuroreport (2011) 22:259-63. doi:10.1097/WNR.0b013e328344495a
85. Lapiz MD, Fulford A, Muchimapura S, Mason R, Parker T, Marsden CA. Influence of postweaning social isolation in the rat on brain development, conditioned behavior, and neurotransmission. Neurosci Behav Physiol (2003) 33:13-29. doi:10.1023/A:1021171129766
86. Fone KC, Porkess MV. Behavioural and neurochemical effects of post-weaning social isolation in rodents-relevance to developmental neuropsychiatric disorders. Neurosci Biobehav Rev (2008) 32:1087-102. doi:10.1016/j.neubiorev.2008.03.003
87. Lipska BK, Jaskiw GE, Weinberger DR. Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia. Neuropsychopharmacology (1993) 9:67-75. doi:10.1038/npp.1993.44
88. Tseng KY, Chambers RA, Lipska BK. The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia. Behav Brain Res (2009) 204:295-305. doi:10.1016/j.bbr.2008.11.039
89. Mei L, Xiong WC. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci (2008) 9:437-52. doi:10.1038/nrn2392
90. Dhakar MB, Rich ME, Reno EL, Lee HJ, Caldwell HK. Heightened aggressive behavior in mice with lifelong versus postweaning knockout of the oxytocin receptor. Horm Behav (2012) 62:86-92. doi:10.1016/j.yhbeh.2012.05.007
91. Young WS III, Shepard E, DeVries AC, Zimmer A, LaMarca ME, Ginns EI, et al. Targeted reduction of oxytocin expression provides insights into its physiological roles. Adv Exp Med Biol (1998) 449:231-40. doi:10.1007/978-1-4615-4871-3_30
92. Huf G, Alexander J, Allen MH, Raveendran NS. Haloperidol plus promethazine for psychosis-induced aggression. Cochrane Database Syst Rev (2009) 3:CD005146. doi:10.1002/14651858.CD005146.pub2
93. Huf G, Alexander J, Allen MH. Haloperidol plus promethazine for psychosis induced aggression. Cochrane Database Syst Rev (2005) 4:CD005146.10.1002/14651858.CD005146.pub2
94. Hershenberg R, Gros DF, Brawman-Mintzer O. Role of atypical antipsychotics in the treatment of generalized anxiety disorder. CNS Drugs (2014) 28:519-33. doi:10.1007/s40263-014-0162-6
95. Buckley PF. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials. Curr Med Res Opin (2004) 20:1357-63. doi:10.1185/030079904125004510
96. Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther (2001) 23:1839-54. doi:10.1016/S0149-2918(00)89080-3
97. Carpenter WT, Koenig JI. The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology (2008) 33:2061-79. doi:10.1038/sj.npp.1301639
98. Schmitt A, Malchow B, Hasan A, Falkai P. The impact of environmental factors in severe psychiatric disorders. Front Neurosci (2014) 8:19. doi:10.3389/fnins.2014.00019
99. Jones CA, Watson DJ, Fone KC. Animal models of schizophrenia. Br J Pharmacol (2011) 164:1162-94. doi:10.1111/j.1476-5381.2011.01386.x
100. Robinson TE, Becker JB. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res (1986) 396:157-98. doi:10.1016/0165-0173(86)90002-0
101. Featherstone RE, Rizos Z, Kapur S, Fletcher PJ. A sensitizing regimen of amphetamine that disrupts attentional set-shifting does not disrupt working or long-term memory. Behav Brain Res (2008) 189:170-9. doi:10.1016/j.bbr.2007.12.032
102. Featherstone RE, Kapur S, Fletcher PJ. The amphetamine-induced sensitized state as a model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2007) 31:1556-71. doi:10.1016/j.pnpbp.2007.08.025
103. Kalinichev M, Robbins MJ, Hartfield EM, Maycox PR, Moore SH, Savage KM, et al. Comparison between intraperitoneal and subcutaneous phencyclidine administration in Sprague-Dawley rats: a locomotor activity and gene induction study. Prog Neuropsychopharmacol Biol Psychiatry (2008) 32:414-22. doi:10.1016/j.pnpbp.2007.09.008
104. Sams-Dodd F. Distinct effects of d-amphetamine and phencyclidine on the social behaviour of rats. Behav Pharmacol (1995) 6:55-65. doi:10.1097/00008877-199501000-00009
105. Lee PR, Brady DL, Shapiro RA, Dorsa DM, Koenig JI. Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin. Neuropsychopharmacology (2005) 30:1883-94. doi:10.1038/sj.npp.1300722
106. Qiao H, Noda Y, Kamei H, Nagai T, Furukawa H, Miura H, et al. Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment. Neuroreport (2001) 12:11-5. doi:10.1097/00001756-200101220-00010
107. Mansbach RS, Geyer MA. Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology (1989) 2:299-308. doi:10.1016/0893-133X(89)90035-3
108. Egerton A, Reid L, McKerchar CE, Morris BJ, Pratt JA. Impairment in perceptual attentional set-shifting following PCP administration: a rodent model of set-shifting deficits in schizophrenia. Psychopharmacology (2005) 179:77-84. doi:10.1007/s00213-004-2109-y
109. Nestler EJ, Hyman SE. Animal models of neuropsychiatric disorders. Nat Neurosci (2010) 13:1161-9. doi:10.1038/nn.2647
110. Olff M, Frijling JL, Kubzansky LD, Bradley B, Ellenbogen MA, Cardoso C, et al. The role of oxytocin in social bonding, stress regulation and mental health: an update on the moderating effects of context and interindividual differences. Psychoneuroendocrinology (2013) 38:1883-94. doi:10.1016/j.psyneuen.2013.06.019
111. Bartz JA, Zaki J, Bolger N, Ochsner KN. Social effects of oxytocin in humans: context and person matter. Trends Cogn Sci (2011) 15:301-9. doi:10.1016/j.tics.2011.05.002
112. Heim C, Young LJ, Newport DJ, Mletzko T, Miller AH, Nemeroff CB. Lower CSF oxytocin concentrations in women with a history of childhood abuse. Mol Psychiatry (2009) 14:954-8. doi:10.1038/mp.2008.112
113. Opacka-Juffry J, Mohiyeddini C. Experience of stress in childhood negatively correlates with plasma oxytocin concentration in adult men. Stress (2012) 15:1-10. doi:10.3109/10253890.2011.560309
114. Pierrehumbert B, Torrisi R, Laufer D, Halfon O, Ansermet F, Beck Popovic M. Oxytocin response to an experimental psychosocial challenge in adults exposed to traumatic experiences during childhood or adolescence. Neuroscience (2010) 166:168-77. doi:10.1016/j.neuroscience.2009.12.016
115. Fries ABW, Ziegler TE, Kurian JR, Jacoris S, Pollak SD. Early experience in humans is associated with changes in neuropeptides critical for regulating social behavior. Proc Natl Acad Sci USA (2005) 102:17237-40. doi:10.1073/pnas.0504767102
116. Legros JJ, Gazzotti C, Carvelli T, Franchimont P, Timsit-Berthier M, von Frenckell R, et al. Apomorphine stimulation of vasopressin- and oxytocin-neurophysins. Evidence for increased oxytocinergic and decreased vasopressinergic function in schizophrenics. Psychoneuroendocrinology (1992) 17:611-7. doi:10.1016/0306-4530(92)90019-4
117. Strauss GP, Keller WR, Koenig JI, Gold JM, Frost KH, Buchanan RW. Plasma oxytocin levels predict social cue recognition in individuals with schizophrenia. Schizophr Res (2015) 162:47-51. doi:10.1016/j.schres.2015.01.034
118. Strauss GP, Keller WR, Koenig JI, Gold JM, Ossenfort KL, Buchanan RW. Plasma oxytocin levels predict olfactory identification and negative symptoms in individuals with schizophrenia. Schizophr Res (2015) 162:57-61. doi:10.1016/j.schres.2014.12.023
119. Jobst A, Dehning S, Ruf S, Notz T, Buchheim A, Henning-Fast K, et al. Oxytocin and vasopressin levels are decreased in the plasma of male schizophrenia patients. Acta Neuropsychiatr (2014) 26:347-55. doi:10.1017/neu.2014.20
120. Sasayama D, Hattori K, Teraishi T, Hori H, Ota M, Yoshida S, et al. Negative correlation between cerebrospinal fluid oxytocin levels and negative symptoms of male patients with schizophrenia. Schizophr Res (2012) 139:201-6. doi:10.1016/j.schres.2012.06.016
121. Keri S, Kiss I, Kelemen O. Sharing secrets: oxytocin and trust in schizophrenia. Soc Neurosci (2009) 4:287-93. doi:10.1080/17470910802319710
122. Oreland S, Gustafsson-Ericson L, Nylander I. Short- and long-term consequences of different early environmental conditions on central immunoreactive oxytocin and arginine vasopressin levels in male rats. Neuropeptides (2010) 44:391-8. doi:10.1016/j.npep.2010.06.001
123. Lukas M, Bredewold R, Neumann ID, Veenema AH. Maternal separation interferes with developmental changes in brain vasopressin and oxytocin receptor binding in male rats. Neuropharmacology (2010) 58:78-87. doi:10.1016/j.neuropharm.2009.06.020
124. Wang L, Zhang W, Wu R, Kong L, Feng W, Cao Y, et al. Neuroendocrine responses to social isolation and paternal deprivation at different postnatal ages in mandarin voles. Dev Psychobiol (2014) 56:1214-28. doi:10.1002/dev.21202
125. de Souza MA, Centenaro LA, Menegotto PR, Henriques TP, Bonini J, Achaval M, et al. Prenatal stress produces social behavior deficits and alters the number of oxytocin and vasopressin neurons in adult rats. Neurochem Res (2013) 38:1479-89. doi:10.1007/s11064-013-1049-5
126. Lee PR, Brady DL, Shapiro RA, Dorsa DM, Koenig JI. Prenatal stress generates deficits in rat social behavior: Reversal by oxytocin. Brain Res (2007) 1156:152-67. doi:10.1016/j.brainres.2007.04.042
127. Young KA, Liu Y, Gobrogge KL, Wang H, Wang Z. Oxytocin reverses amphetamine-induced deficits in social bonding: evidence for an interaction with nucleus accumbens dopamine. J Neurosci (2014) 34:8499-506. doi:10.1523/JNEUROSCI.4275-13.2014
128. Ferguson JN, Young LJ, Hearn EF, Matzuk MM, Insel TR, Winslow JT. Social amnesia in mice lacking the oxytocin gene. Nat Genet (2000) 25:284-8. doi:10.1038/77040
129. Pobbe RL, Pearson BL, Blanchard DC, Blanchard RJ. Oxytocin receptor and Mecp2 308/Y knockout mice exhibit altered expression of autism-related social behaviors. Physiol Behav (2012) 107:641-8. doi:10.1016/j.physbeh.2012.02.024
130. Pobbe RL, Pearson BL, Defensor EB, Bolivar VJ, Young WS III, Lee HJ, et al. Oxytocin receptor knockout mice display deficits in the expression of autism-related behaviors. Horm Behav (2012) 61:436-44. doi:10.1016/j.yhbeh.2011.10.010
131. Winslow JT, Hearn EF, Ferguson J, Young LJ, Matzuk MM, Insel TR. Infant vocalization, adult aggression, and fear behavior of an oxytocin null mutant mouse. Horm Behav (2000) 37:145-55. doi:10.1006/hbeh.1999.1566
132. Macbeth AH, Stepp JE, Lee HJ, Young WS III, Caldwell HK. Normal maternal behavior, but increased pup mortality, in conditional oxytocin receptor knockout females. Behav Neurosci (2010) 124:677-85. doi:10.1037/a0020799
133. Rich ME, deCardenas EJ, Lee HJ, Caldwell HK. Impairments in the initiation of maternal behavior in oxytocin receptor knockout mice. PLoS One (2014) 9:e98839. doi:10.1371/journal.pone.0098839
134. Boccia ML, Pedersen CA. Brief vs. long maternal separations in infancy: contrasting relationships with adult maternal behavior and lactation levels of aggression and anxiety. Psychoneuroendocrinology (2001) 26:657-72. doi:10.1016/S0306-4530(01)00019-1
135. Padoin MJ, Cadore LP, Gomes CM, Barros HM, Lucion AB. Long-lasting effects of neonatal stimulation on the behavior of rats. Behav Neurosci (2001) 115:1332-40. doi:10.1037/0735-7044.115.6.1332
136. Patin V, Lordi B, Vincent A, Caston J. Effects of prenatal stress on anxiety and social interactions in adult rats. Brain Res Dev Brain Res (2005) 160:265-74. doi:10.1016/j.devbrainres.2005.09.010
137. Nelson RJ, Trainor BC. Neural mechanisms of aggression. Nat Rev Neurosci (2007) 8:536-46. doi:10.1038/nrn2174
138. Champagne F, Diorio J, Sharma S, Meaney MJ. Naturally occurring variations in maternal behavior in the rat are associated with differences in estrogen-inducible central oxytocin receptors. Proc Natl Acad Sci USA (2001) 98:12736-41. doi:10.1073/pnas.221224598
139. Francis DD, Champagne FC, Meaney MJ. Variations in maternal behaviour are associated with differences in oxytocin receptor levels in the rat. J Neuroendocrinol (2000) 12:1145-8. doi:10.1046/j.1365-2826.2000.00599.x
140. Pena CJ, Neugut YD, Calarco CA, Champagne FA. Effects of maternal care on the development of midbrain dopamine pathways and reward-directed behavior in female offspring. Eur J Neurosci (2014) 39:946-56. doi:10.1111/ejn.12479
141. Young LJ, Lim MM, Gingrich B, Insel TR. Cellular mechanisms of social attachment. Horm Behav (2001) 40:133-8. doi:10.1006/hbeh.2001.1691
142. Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology (1999) 20:201-25. doi:10.1016/S0893-133X(98)00060-8
143. Moghaddam B, Jackson ME. Glutamatergic animal models of schizophrenia. Ann N Y Acad Sci (2003) 1003:131-7. doi:10.1196/annals.1300.065
144. Melis MR, Melis T, Cocco C, Succu S, Sanna F, Pillolla G, et al. Oxytocin injected into the ventral tegmental area induces penile erection and increases extracellular dopamine in the nucleus accumbens and paraventricular nucleus of the hypothalamus of male rats. Eur J Neurosci (2007) 26:1026-35. doi:10.1111/j.1460-9568.2007.05721.x
145. Succu S, Sanna F, Cocco C, Melis T, Boi A, Ferri GL, et al. Oxytocin induces penile erection when injected into the ventral tegmental area of male rats: role of nitric oxide and cyclic GMP. Eur J Neurosci (2008) 28:813-21. doi:10.1111/j.1460-9568.2008.06385.x
146. Baskerville TA, Allard J, Wayman C, Douglas AJ. Dopamine-oxytocin interactions in penile erection. Eur J Neurosci (2009) 30:2151-64. doi:10.1111/j.1460-9568.2009.06999.x
147. Freund-Mercier MJ, Stoeckel ME, Klein MJ. Oxytocin receptors on oxytocin neurones: histoautoradiographic detection in the lactating rat. J Physiol (1994) 480(Pt 1):155-61. doi:10.1113/jphysiol.1994.sp020349
148. Yoshimura R, Kiyama H, Kimura T, Araki T, Maeno H, Tanizawa O, et al. Localization of oxytocin receptor messenger ribonucleic acid in the rat brain. Endocrinology (1993) 133:1239-46. doi:10.1210/endo.133.3.8396014
149. Love TM. Oxytocin, motivation and the role of dopamine. Pharmacol Biochem Behav (2014) 119:49-60. doi:10.1016/j.pbb.2013.06.011
150. Curras-Collazo MC, Gillard ER, Jin J, Pandika J. Vasopressin and oxytocin decrease excitatory amino acid release in adult rat supraoptic nucleus. J Neuroendocrinol (2003) 15:182-90. doi:10.1046/j.1365-2826.2003.00976.x
151. Osako Y, Otsuka T, Taniguchi M, Oka T, Kaba H. Oxytocin enhances presynaptic and postsynaptic glutamatergic transmission between rat olfactory bulb neurones in culture. Neurosci Lett (2001) 299:65-8. doi:10.1016/S0304-3940(00)01779-1
152. Knobloch HS, Charlet A, Hoffmann LC, Eliava M, Khrulev S, Cetin AH, et al. Evoked axonal oxytocin release in the central amygdala attenuates fear response. Neuron (2012) 73:553-66. doi:10.1016/j.neuron.2011.11.030
153. Lee HJ, Caldwell HK, Macbeth AH, Tolu SG, Young WS III. A conditional knockout mouse line of the oxytocin receptor. Endocrinology (2008) 149:3256-63. doi:10.1210/en.2007-1710
154. Ferguson JN, Aldag JM, Insel TR, Young LJ. Oxytocin in the medial amygdala is essential for social recognition in the mouse. J Neurosci (2001) 21:8278-85.
155. Bruce HM, Parrott DM. Role of olfactory sense in pregnancy block by strange males. Science (1960) 131:1526. doi:10.1126/science.131.3412.1526
156. Bruce HM. A block to pregnancy in the mouse caused by proximity of strange males. J Reprod Fertil (1960) 1:96-103. doi:10.1530/jrf.0.0010096
157. DeVries AC, Young WS III, Nelson RJ. Reduced aggressive behaviour in mice with targeted disruption of the oxytocin gene. J Neuroendocrinol (1997) 9:363-8. doi:10.1046/j.1365-2826.1997.t01-1-00589.x
158. Macbeth AH, Lee HJ, Edds J, Young WS III. Oxytocin and the oxytocin receptor underlie intrastrain, but not interstrain, social recognition. Genes Brain Behav (2009) 8:558-67. doi:10.1111/j.1601-183X.2009.00506.x
159. Park JM, Solomon P, Mandell DS. Involvement in the child welfare system among mothers with serious mental illness. Psychiatr Serv (2006) 57:493-7. doi:10.1176/appi.ps.57.4.493
160. Reupert A, Maybery D. Families affected by parental mental illness: a multiperspective account of issues and interventions. Am J Orthopsychiatry (2007) 77:362-9. doi:10.1037/0002-9432.77.3.362
161. Lagan M, Knights K, Barton J, Boyce PM. Advocacy for mothers with psychiatric illness: a clinical perspective. Int J Ment Health Nurs (2009) 18:53-61. doi:10.1111/j.1447-0349.2008.00576.x
162. Millstein RA, Ralph RJ, Yang RJ, Holmes A. Effects of repeated maternal separation on prepulse inhibition of startle across inbred mouse strains. Genes Brain Behav (2006) 5:346-54. doi:10.1111/j.1601-183X.2005.00172.x
163. Braff D. Psychophysiological and information processing approaches to schizophrenia. In: Charney DS, Bunney BS, editors. Foundations of Mental Illness. Oxford, NY: Oxford University Press (1999). p. 258-71.
164. Perry W, Feifel D, Minassian A, Bhattacharjie I, Braff DL. Information processing deficits in acutely psychotic schizophrenia patients medicated and unmedicated at the time of admission. Am J Psychiatry (2002) 159:1375-81. doi:10.1176/appi.ajp.159.8.1375
165. Landis CH, Hunt WA. The Startle Pattern. New York, NY: Farrar & Rinehart (1939).
166. Swerdlow NR, Geyer MA, Braff DL. Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology (Berl) (2001) 156:194-215. doi:10.1007/s002130100799
167. Braff DL, Grillon C, Geyer MA. Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry (1992) 49:206-15. doi:10.1001/archpsyc.1992.01820030038005
168. Swerdlow NR, Martinez ZA, Hanlon FM, Platten A, Farid M, Auerbach P, et al. Toward understanding the biology of a complex phenotype: rat strain and substrain differences in the sensorimotor gating-disruptive effects of dopamine agonists. J Neurosci (2000) 20:4325-36.
169. Geyer MA, Braff DL. Habituation of the Blink reflex in normals and schizophrenic patients. Psychophysiology (1982) 19:1-6. doi:10.1111/j.1469-8986.1982.tb02589.x
170. Feifel D, Shilling PD, Belcher AM. The effects of oxytocin and its analog, carbetocin, on genetic deficits in sensorimotor gating. Eur Neuropsychopharmacol (2012) 22:374-8. doi:10.1016/j.euroneuro.2011.09.004
171. Ellenbroek BA, van den Kroonenberg PTJM, Cools AR. The effects of an early stressful life event on sensorimotor gating in adult rats. Schizophr Res (1998) 30:251-60. doi:10.1016/S0920-9964(97)00149-7
172. Feifel D, Reza T. Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating. Psychopharmacology (1999) 141:93-8. doi:10.1007/s002130050811
173. Caldwell HK, Stephens SL, Young WS III. Oxytocin as a natural antipsychotic: a study using oxytocin knockout mice. Mol Psychiatry (2009) 14:190-6. doi:10.1038/sj.mp.4002150
174. Glahn DC, Therman S, Manninen M, Huttunen M, Kaprio J, Lonnqvist J, et al. Spatial working memory as an endophenotype for schizophrenia. Biol Psychiatry (2003) 53:624-6. doi:10.1016/S0006-3223(02)01641-4
175. Sala M, Braida D, Lentini D, Busnelli M, Bulgheroni E, Capurro V, et al. Pharmacologic rescue of impaired cognitive flexibility, social deficits, increased aggression, and seizure susceptibility in oxytocin receptor null mice: a neurobehavioral model of autism. Biol Psychiatry (2011) 69:875-82. doi:10.1016/j.biopsych.2010.12.022
176. Insel TR, Winslow JT, Witt DM. Homologous regulation of brain oxytocin receptors. Endocrinology (1992) 130:2602-8. doi:10.1210/en.130.5.2602
177. Wu W, Yu LC. Roles of oxytocin in spatial learning and memory in the nucleus basalis of Meynert in rats. Regul Pept (2004) 120:119-25. doi:10.1016/j.regpep.2004.02.017
178. Duncan GE, Moy SS, Perez A, Eddy DM, Zinzow WM, Lieberman JA, et al. Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function. Behav Brain Res (2004) 153:507-19. doi:10.1016/j.bbr.2004.01.008
179. Rhee SG, Bae YS. Regulation of phosphoinositide-specific phospholipase C isozymes. J Biol Chem (1997) 272:15045-8. doi:10.1074/jbc.272.24.15045
180. Stoop R. Neuromodulation by oxytocin and vasopressin. Neuron (2012) 76:142-59. doi:10.1016/j.neuron.2012.09.025
181. Kim D, Jun KS, Lee SB, Kang NG, Min DS, Kim YH, et al. Phospholipase C isozymes selectively couple to specific neurotransmitter receptors. Nature (1997) 389:290-3. doi:10.1038/38508
182. Hannan AJ, Kind PC, Blakemore C. Phospholipase C-beta1 expression correlates with neuronal differentiation and synaptic plasticity in rat somatosensory cortex. Neuropharmacology (1998) 37:593-605. doi:10.1016/S0028-3908(98)00056-2
183. Lin XH, Kitamura N, Hashimoto T, Shirakawa O, Maeda K. Opposite changes in phosphoinositide-specific phospholipase C immunoreactivity in the left prefrontal and superior temporal cortex of patients with chronic schizophrenia. Biol Psychiatry (1999) 46:1665-71. doi:10.1016/S0006-3223(99)00036-0
184. Shirakawa O, Kitamura N, Lin XH, Hashimoto T, Maeda K. Abnormal neurochemical asymmetry in the temporal lobe of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2001) 25:867-77. doi:10.1016/S0278-5846(01)00149-X
185. Koh HY, Kim D, Lee J, Lee S, Shin HS. Deficits in social behavior and sensorimotor gating in mice lacking phospholipase Cbeta1. Genes Brain Behav (2008) 7:120-8. doi:10.1111/j.1601-183X.2007.00351.x
186. McOmish CE, Burrows E, Howard M, Scarr E, Kim D, Shin HS, et al. Phospholipase C-beta1 knockout mice exhibit endophenotypes modeling schizophrenia which are rescued by environmental enrichment and clozapine administration. Mol Psychiatry (2008) 13:661-72. doi:10.1038/sj.mp.4002046
187. Arendt T, Bigl V, Arendt A, Tennstedt A. Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's Disease. Acta Neuropathol (1983) 61:101-8. doi:10.1007/BF00697388
188. Jones DNC, Gartlon JE, Minassian A, Perry W, Geyer MA. Developing new drugs for schizophrenia: from animals to the clinic. In: McArthur R, Borsini R, editors. Animal and Translational Models for CNS Drug Discovery: Psychiatric Disorders. New York, NY: Elsevier (2008). p. 199-262.
189. Powell SB, Zhou X, Geyer MA. Prepulse inhibition and genetic mouse models of schizophrenia. Behav Brain Res (2009) 204:282-94. doi:10.1016/j.bbr.2009.04.021
190. Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science (1998) 281:1349-52. doi:10.1126/science.281.5381.1349
191. Homayoun H, Jackson ME, Moghaddam B. Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats. J Neurophysiol (2005) 93:1989-2001. doi:10.1152/jn.00875.2004
192. Ninan I. Oxytocin suppresses basal glutamatergic transmission but facilitates activity-dependent synaptic potentiation in the medial prefrontal cortex. J Neurochem (2011) 119:324-31. doi:10.1111/j.1471-4159.2011.07430.x
193. Emiliano AB, Cruz T, Pannoni V, Fudge JL. The interface of oxytocin-labeled cells and serotonin transporter-containing fibers in the primate hypothalamus: a substrate for SSRIs therapeutic effects? Neuropsychopharmacology (2007) 32:977-88. doi:10.1038/sj.npp.1301206
194. Tyzio R, Nardou R, Ferrari DC, Tsintsadze T, Shahrokhi A, Eftekhari S, et al. Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring. Science (2014) 343:675-9. doi:10.1126/science.1247190
195. Yoshida M, Takayanagi Y, Inoue K, Kimura T, Young LJ, Onaka T, et al. Evidence that oxytocin exerts anxiolytic effects via oxytocin receptor expressed in serotonergic neurons in mice. J Neurosci (2009) 29:2259-71. doi:10.1523/JNEUROSCI.5593-08.2009
196. Eaton JL, Roache L, Nguyen KN, Cushing BS, Troyer E, Papademetriou E, et al. Organizational effects of oxytocin on serotonin innervation. Dev Psychobiol (2012) 54:92-7. doi:10.1002/dev.20566
197. Jorgensen H, Riis M, Knigge U, Kjaer A, Warberg J. Serotonin receptors involved in vasopressin and oxytocin secretion. J Neuroendocrinol (2003) 15:242-9. doi:10.1046/j.1365-2826.2003.00978.x
198. vnas-Moberg KU, Alster P, Svensson TH. Amperozide and clozapine but not haloperidol or raclopride increase the secretion of oxytocin in rats. Psychopharmacology (1992) 109:473-6. doi:10.1007/BF02247726
199. Bjork A, Olsson NG, Christensson E, Martinsson K, Olsson O. Effects of amperozide on biting behavior and performance in restricted-fed pigs following regrouping. J Anim Sci (1988) 66:669-75.
200. Gonyou HW, Parfet KA, Anderson DB, Olson RD. Effects of amperozide and azaperone on aggression and productivity of growing-finishing pigs. J Anim Sci (1988) 66:2856-64.
201. Egbe PC. Locomotor effects of amperozide. Antagonism of amphetamine-induced locomotor stimulation. Arzneimittelforschung (1989) 39:1223-4.
202. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther (1989) 251:238-46.
203. Ayd FJ Jr. Haloperidol: fifteen years of clinical experience. Dis Nerv Syst (1972) 33:459-69.
204. Ayd FJ Jr. Haloperidol: twenty years' clinical experience. J Clin Psychiatry (1978) 39:807-14.
205. Kiss A, Bundzikova J, Pirnik Z, Mikkelsen JD. Different antipsychotics elicit different effects on magnocellular oxytocinergic and vasopressinergic neurons as revealed by Fos immunohistochemistry. J Neurosci Res (2010) 88:677-85. doi:10.1002/jnr.22226
206. Abdul-Monim Z, Reynolds GP, Neill JC. The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. Behav Brain Res (2006) 169:263-73. doi:10.1016/j.bbr.2006.01.019
207. Feifel D, Shilling PD, Melendez G. Clozapine and PD149163 elevate prepulse inhibition in Brown Norway rats. Behav Neurosci (2011) 125:268-72. doi:10.1037/a0022691
208. Ciapparelli A, Ducci F, Carmassi C, Carlini M, Paggini R, Catena M, et al. Predictors of response in a sample of treatment-resistant psychotic patients on clozapine. Eur Arch Psychiatry Clin Neurosci (2004) 254:343-6. doi:10.1007/s00406-004-0511-4
209. Kane JM, Honigfeld G, Singer J, Meltzer H. Clozapine in treatment-resistant schizophrenics. Psychopharmacol Bull (1988) 24:62-7.
210. Kaneda Y, Jayathilak K, Meltzer H. Determinants of work outcome in neuroleptic-resstant schizophrenia and schizoaffective disorder: cognitive impairment and clozapine treatment. Psychiatry Res (2010) 178:57-62. doi:10.1016/j.psychres.2009.04.001
211. Tiihonen J, Leucht S. Clozapine resistance-augmentation strategies. Eur Neuropsychopharmacol (2013) 23:338. doi:10.1016/j.euroneuro.2012.04.020
212. Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT Jr. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry (1998) 155:751-60.